Drug
Sovleplenib clinical trials
Also written HMPL-523.
Includes 1 study of Sovleplenib acetate.
- studies test it
- 15
- open now
- 0
- in phase 3
- 2
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
- HMPL-523
- 13
Studies by the year they started
15 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 12
- Phase 2
- 1
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Itraconazole (1) · Rifampin (1) · Rabeprazole (1) · Azacitidine (1)
Studies
Open first, then newest update. How each study uses sovleplenib is read from its arms, and is right about nine times in ten.
Testing it · 15
- HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaActive, not recruitingPhase 2/3HutchmedNCT05535933Written as HMPL-523(300mg PO QD)
- Phase III Study on HMPL-523 for Treatment of ITPCompletedPhase 3HutchmedNCT05029635Written as HMPL-523
- An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedPhase 1HutchmedNCT03779113Written as HMPL-523
- Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate TabletsCompletedPhase 1HutchmedNCT07348133Written as HMPL-523
- Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in HumansCompletedPhase 1HutchmedNCT07331194Written as HMPL-523 Acetate Tablets (Test Formulation)
- The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)WithdrawnPhase 1HutchmedNCT06291415Written as HMPL-523
- The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsCompletedPhase 1Hutchison Medipharma LimitedNCT03951623Written as HMPL-523
- Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese SubjectsCompletedPhase 1HutchmedNCT05781906Written as HMPL-523
- A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell NeoplasmsCompletedPhase 1Hutchison Medipharma LimitedNCT02857998Written as HMPL-523
- A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different ManufacturersCompletedEarly Phase 1Hutchison Medipharma LimitedNCT05318820Written as HMPL-523
- HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer StudyCompletedPhase 1HutchmedNCT05720767Written as HMPL-523
- HMPL-523 Food Effect and Proton Pump Inhibitor StudyCompletedPhase 1HutchmedNCT05571787Written as HMPL-523
- A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesStatus unknownPhase 1Hutchison Medipharma LimitedNCT02503033Written as HMPL-523
- Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid LeukemiaTerminatedPhase 1Hutchison Medipharma LimitedNCT03483948Written as HMPL-523
- A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523CompletedPhase 1Hutchison Medipharma LimitedNCT02105129Written as HMPL-523
Codes
What other systems call sovleplenib · ClinicalTrials.gg INT015846
- UNII (FDA) 9CL6353KHOSOVLEPLENIBOne source FDA
- NCI Thesaurus C123912SovleplenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9CL6353KHO | SOVLEPLENIB | One source FDA |
| NCI Thesaurus | C123912 | Sovleplenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.